Beijing Qingke Biotechnology

Beijing Tsingke Biotechnology Co., Ltd. operates as a vertically integrated gene synthesis platform, establishing a significant footprint in the synthetic biology sector since its inception. Founded in 2017, the company is headquartered in Beijing, China, and has expanded its operations to include numerous laboratories and entities across the country, as well as extending its business to the United States and Germany. Tsingke serves a global client base of over 170,000 users, including academia, pharmaceutical companies, and research institutions.

The company's business model is structured around three core pillars: synthetic genomics products and services, life science research equipment and raw materials, and biomanufacturing as a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO). This integrated approach allows Tsingke to control the entire gene synthesis industrial chain. Revenue is generated by providing a comprehensive suite of products and services, including oligo synthesis, gene synthesis, protein expression, and antibody services. The company has positioned itself as an upstream enterprise in the synthetic biology ecosystem, providing the foundational technologies and materials for the industry.

Tsingke has developed what it terms a "Gene Factory," an intelligent and automated production platform. This platform combines proprietary molecular resolution and synthesis technology with the TSINGKE HELIXTECH AI algorithm system to connect raw materials, equipment, and processes for efficient production. Key offerings include Tsynth™ Gene Synthesis, which can produce gene lengths up to 200 kb, and versatile oligo synthesis solutions with over 200 modifications. The company also provides services for protein expression, antibody production, gene regulation, and sequencing. This technological infrastructure is supported by a significant R&D site and a 100,000-grade clean production workshop.

Since its founding, the company has achieved significant financial milestones, securing a Series B funding round of over CNY 400 million (approximately $57 million) in December 2022. This funding, led by investors such as Henan Investment Group Huirong Fund and Fortune Capital, was earmarked for further R&D investment in its "gene factory," technology platform upgrades, talent acquisition, and global expansion. By January 2022, the company had also completed a Series A round, contributing to a total raised amount of over $87 million. Tsingke's commitment to innovation is evidenced by its portfolio of over 300 intellectual property rights.

Keywords: synthetic genomics, gene synthesis, DNA/RNA synthesis, oligo synthesis, synthetic biology, biomanufacturing, CRO, CDMO, life science raw materials, protein expression, antibody services, molecular biology, gene technology, nucleic acid synthesis, genetic research, biotechnology, DNA sequencing, IVD raw materials, nucleic acid drug development, gene factory